Contributions
Abstract: EP1672
Type: Poster Sessions
Abstract Category: Therapy - Risk management for disease modifying treatments
This report will detail a case of immune-mediated encephalitis in the context of daclizumab therapy. Daclizumab is a humanised monoclonal antibody which, prior to its recent worldwide withdrawal due to safety concerns, was utilised as a disease modifying therapy in relapsing-remitting multiple sclerosis. The withdrawal of this therapy was prompted by concerns over twelve cases of serious immune-mediated adverse reactions in the central nervous system. We report an additional case, including clinical data and results of neuroimaging, CSF examination and brain biopsy
Disclosure: For all authors: Nil to declare.
Abstract: EP1672
Type: Poster Sessions
Abstract Category: Therapy - Risk management for disease modifying treatments
This report will detail a case of immune-mediated encephalitis in the context of daclizumab therapy. Daclizumab is a humanised monoclonal antibody which, prior to its recent worldwide withdrawal due to safety concerns, was utilised as a disease modifying therapy in relapsing-remitting multiple sclerosis. The withdrawal of this therapy was prompted by concerns over twelve cases of serious immune-mediated adverse reactions in the central nervous system. We report an additional case, including clinical data and results of neuroimaging, CSF examination and brain biopsy
Disclosure: For all authors: Nil to declare.